摘要
目的:对多发性骨髓瘤(MM)患者应用硼替佐米治疗的临床效果进行探讨与研究。方法:初治MM患者48例,分成研究组和对照组,每组24例。研究组给予BDT方案治疗(硼替佐米+地塞米松+沙利度胺),对照组给予CDT方案治疗(环磷酰胺+地塞米松+沙利度胺)。对2组的诱导化疗效果进行观察与对比。结果:研究组中有10例CR(41.7%),6例VGPR(25%),4例PR(16.6%),3例SD(12.5%),1例PD,OR率为83.3%。对照组中有2例CR(8.3%),3例VGPR(12.5%),10例PR(41.7%),7例SD(29.1%),2例PD(8.3%),OR率为62.5%。2组比较差异有统计学意义(P<0.05)。研究组患者的不良反应发生率为29.2%,对照组患者为16.7%,差异无统计学意义(P>0.05),其中周围神经病变、血小板减少、感染等是主要不良反应。结论:硼替佐米方案治疗MM的效果显著,能够改善患者的生存质量和预后,安全可靠,尽管会出现一些不良反应,但作为靶向性治疗新药,由硼替佐米组成的治疗方案是值得在临床推广。
Objective：To study and research the clinical effect of multiple myeloma patients treated with borte zomib. Method：48 cases of newly diagnosed Multiple Myeloma （MM） patients were divided into study group and control group,24 cases in each group. The study group were treated by BDT regimen in the treatment （bortezomib ＋ dexamethasone ＋ thalidomide）, the control group were given CDT regimen in the treatment （cyclophosphamide ＋ dexamethasone ＋ thalidomide）. Result：In the study group, there were 10 cases of CR （41.7 % ）, 6 cases of VG PR （25%）,4 cases of PR （16.6%）,3 cases of SD （12.5%）,1 cases of PD and OR rate was 83.3%. In the control group,there were 2 cases of CR （8. 3%）,3 cases of VGPR （12. 5%）,10 cases of PR （41. 7%）,7 cases of SD （29.1%） ,2 cases of PD （8.3%）and OR rate was 62.5% ,with statistical significance （P〈0.05）. The adverse re- actions of the patients in the study groups the incidence rate was 29.2 %, the patients of control group was 16.7%, without statistical significant （P〈0.05）, the main adverse reaction is peripheral neuropathy, thrombocytopenia and infection. Conclusion： Effect of bortezomib for the treatment of multiple myeloma can significantly improve the life quality and the prognosis of the patients, which is safe and reliable. Although there were some adverse reactions, as a targeted therapy,treatment with bortezomib is worth clinical promoting.
出处
《临床血液学杂志》
CAS
2015年第3期406-407,411,共3页
Journal of Clinical Hematology
基金
云南省卫生科技计划项目(No:2011WS0002)
